Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Small intestinal neuroendocrine tumours, drawn from the whole corpus: 20 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No randomised trial orders radioligand therapy, everolimus and cabozantinib after somatostatin analogues.
Whether removing the primary improves survival in patients with liver metastases has never been tested prospectively.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Chromogranin A is unreliable and no blood test yet replaces imaging for follow-up.
Overall survival gains are hard to show because patients live for years and cross over.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 18 changes by month →When this page itself was last checked or edited.
Acromegaly in adults
PFS 23.
A milestone in how this cancer is treated.
PFS HR 0.
A milestone in how this cancer is treated.